Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
- Japan to Grant Total of 90 Billion Yen to 6 Firms for COVID-19 Vaccine Production
August 11, 2020
- MHLW Warns of COVID-Tied Cyberattacks, Urges Companies to Boost Measures
August 7, 2020
- Tsutomu Iuchi to Lead MHLW's Medical Economics Division
August 6, 2020
- NIBIOHN, US Biotech to Develop COVID-19 Replicon RNA Vaccine; Japan PII Eyed Next Summer
August 5, 2020
- Japan Sketches Out Stable API Supply Measures, Set to Pick Key Drugs from 551 Candidates by March-End
August 4, 2020
- Tetsunari Kihira Appointed as Pharmaceutical Management Director
August 4, 2020
- Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
- PMDA Reviewing Safety Risks for Plaquenil, Relumina
August 3, 2020
- PMDA Provided Preliminary Info on MID-NET Use for Free in “Just Under 10 Cases”: Official
July 31, 2020
- MHLW Finds 57 Suspected Violations in Drug Detailing Activities in FY2019
July 30, 2020
- AMED’s Drug Discovery Library under CiCLE Program Ready to Start Operations
July 30, 2020
- AMED Selects 2 Anti-COVID-19 Projects under CiCLE Grant Program
July 30, 2020
- HPV Vaccines Clinically Significant in Japan, PMDA Says in Silgard 9 Review Report
July 28, 2020
- Dexamethasone Added to MHLW’s COVID-19 Guide
July 27, 2020
- Chuikyo OKs Plan for September Drug Price Survey, Smaller Coverage amid COVID-19
July 22, 2020
- Reinstate “Active Recommendation” for HPV Vaccines: LDP Lawmakers’ League
July 22, 2020
- Label Revisions Ordered for Iopamiron, 5 Other Contrast Media
July 22, 2020
- September Drug Price Survey Likely as MHLW to Keep Its Proposal Unchanged
July 21, 2020
- Kadcyla, Keytruda, Imfinzi in Line for Label Expansion in August
July 20, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…